Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study

Asian Journal of Psychiatry

Volumn 6, Issue 2, 2013, Pages 157-161

  Ravindran, Arun V ^a,b,c   Cameron, Colin ^c   Bhatla, Raj ^c   Ravindran, Lakshmi N ^a,b   Da Silva, Tricia L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Dysthymic disorder; Paroxetine; Placebo; Randomized controlled trial; Selective serotonin reuptake inhibitors

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; ADVERSE OUTCOME; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSTHYMIA; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREATMENT RESPONSE;

ADULT; DOUBLE-BLIND METHOD; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875364776     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2012.10.004     Document Type: Article

References (35)

1. Akiskal H.S. Towards a definition of dysthymia: boundaries with personality and mood disorders. Dysthymic Disorder 1990, 1-12. Gaskell, London, London. S.W. Burton, H.S. Akiskal (Eds.).
2. Akiskal H.S. Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. Journal of Affective Disorders 2001, 62(1-2):17-31.
3. Akiskal H.S., Cassano G.B. Dysthymia and the Spectrum of Chronic Depressions 1997, Guilford Press, New York.
4. American Psychiatric Association The Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington. 4th edition, text revision.
5. Bagby R.M., Ryder A.G., Schuller D.R., Marshall M.B. The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. American Journal of Proctology 2004, 161(12):2163-2177.
6. Baldwin D.S., Lopes A.T.V. The influence of comorbid anxiety disorders on outcome in major depressive disorder. Mediocographia 2009, 31:126-131.
7. Ballús C., Quiros G., De Flores T., de la Torre J., Palao D., Rojo L., Gutierrez M., Casais L., Riesgo Y. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. International Clinical Psychopharmacology 2000, 15(1):43-48.
8. Barrett J.E., Williams J.W., Oxman T.E., Frank E., Katon W., Sullivan M., Hegel M.T., Cornell J.E., Sengupta A.S. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18-59 years. Journal of Family Practice 2001, 50(5):405-412.
9. Beck A.T., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
10. Boylan K.R., Bieling P.J., Marriott M., Begin H., Young L.T., MacQueen G.M. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Journal of Clinical Psychiatry 2004, 65(8):1106-1113.
11. Browne G., Steiner M., Roberts J., Gafni A., Byrne C., Dunn E., Bell B., Mills M., Chalklin L., Wallik D., Kraemer J. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. Journal of Affective Disorders 2002, 68(2-3):317-330.
12. De Lima M.S., Hotoph M., Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine 1999, 29(6):1273-1289.
13. Endicott J., Nee J., Harrison W., Blumnethal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacology Bulletin 1993, 29(2):321-326.
14. Freeman H.L. Historical and nosological aspects of dysthymia. Acta Psychiatrica Scandinavica 1994, 383(Suppl.):7-11.
15. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social & Clinical Psychology 1967, 6(4):278-296.
16. Haykal R.F., Akiskal H.S. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. Journal of Clinical Psychiatry 1999, 60(8):508-518.
17. Hellerstein D.J., Batchelder S., Miozzo R., Kreditor D., Hyler S., Gangure D., Clark J. Citalopram in the treatment of dysthymic disorder. International Clinical Psychopharmacology 2004, 19(3):143-148.
18. Hofmeijer-Sevink M.K., Batelaan N.M., van Megen H.J., Penninx B.W., Cath D.C., van den Hout M.A., van Balkom A.J. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). Journal of Affective Disorders 2012, 137(1-3):106-112.
19. Keller M.B., Gelenberg A.J., Hirschfeld R.M., Rush A.J., Thase M.E., Kocsis J.H., Markowitz J.C., Fawcett J.A., Koran L.M., Klein D.N., Russell J.M., Kornstein S.G., McCullough J.P., Davis S.M., Harrison W.M. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry 1998, 59(11):598-607.
20. Klein D.N., Shankman S.A., Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. American Journal of Proctology 1999, 163(5):872-880.
21. Levkovitz Y., Tedeschini E., Papakostas G.I. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry 2011, 72(4):509-514.
22. Pini S., Amador X.F., Dell'Osso L., Baldini Rossi N., Cassano P., Savino M., Cassano G.B. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. International Clinical Psychopharmacology 2003, 18(1):15-21.
23. Ravindran A.V., Guelfi J.D., Lane R.M., Cassano G.B. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of Clinical Psychiatry 2000, 61(11):821-827.
24. Rocca P., Fonzo V., Ravizza L., Rocca G., Scotta M., Zanalda E., Bogetto F. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. Journal of Affective Disorders 2002, 70(3):313-317.
25. Rocca P., Marchiaro L., Rasetti R., Rivoira E., Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Research 2002, 112(2):145-152.
26. Serrano-Blanco A., Gabarron E., Garcia-Bayo I., Soler-Vila M., Carames E., Penarrubia-Maria M.T., Pinto-Meza A., Haro J.M., Depressió en Atenció Primària de Gavà Group (D.A.P.G.A.) Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. Journal of Affective Disorders 2006, 91(2-3):153-163.
27. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
28. Sinaikin P.M. A clinically relevant guide to the differential diagnosis of depression. Journal of Nervous and Mental Disease 1985, 173(4):199-211.
29. Svanborg C., Wistedt A.A., Svanborg P. Long-term outcome of patients with dysthymia and panic disorder: a naturalistic 9-year follow-up study. Nordic Journal of Psychiatry 2008, 62(1):17-24.
30. Taylor M.J., Freemantle N., Geddes J.R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry 2006, 63(11):1217-1223.
31. Thase M.E., Fava M., Halbreich U., Kocsis J.H., Koran L., Davidson J., Rosenbaum J., Harrison W. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry 1996, 53(9):777-784.
32. Thompson C. Onset of action of antidepressants: results of different analyses. Human Psychopharmacology 2002, 17(Suppl. 1):S27-S32.
33. Vanelle J.M., Attar-Levy D., Poirier M.F., Bouhassira M., Blin P., Olie J.P. Controlled efficacy study of fluoxetine in dysthymia. British Journal of Psychiatry 1997, 170:345-350.
34. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., Goa K.L. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002, 62(10):655-703.
35. Williams J.W., Barrett J., Oxman T., Frank E., Katon W., Sullivan M., Cornell J., Sengupta A. Treatment of dysthymia and minor depression in primary care: a randomized trial in older adults. JAMA: The Journal of the American Medical Association 2000, 284(12):1519-1526.